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Background: Gestational diabetes mellitus (GDM) is associated with an elevated risk of adverse health outcomes
such as type 2 diabetes and cardiovascular diseases. Carotid intima-media thickness (cIMT) is increasingly used as a
noninvasive marker for subclinical atherosclerosis. Whether there is a direct correlation between GDM and elevated
cIMT is still controversial.
Methods: PubMed, Embase and reference lists of relevant papers were reviewed. Studies assessing the relationship
between GDM and cIMT were included. Weighted Mean Difference (WMD) of cIMT was calculated using
random-effect models.
Results: Fifteen studies with a total of 2247 subjects were included in our analysis, giving a pooled WMD of 0.05
(95% confidence interval [CI] 0.03 –0.07). Furthermore, meta regression and subgroup analysis found that the
association between GDM and larger cIMT already existed during pregnancy, and this relation was stronger in
obese GDM patients.
Conclusions: GDM in and after pregnancy is associated with subclinical atherosclerosis. Weight control may be
helpful to prevent cardiovascular diseases for GDM patients.
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Gestational diabetes mellitus (GDM) is one of the com-
mon complications during pregnancy, which incidence is
approximately 5% (range from 1 to 14%) and this num-
ber is increasing due to increased prevalence of obesity
[1]. GDM women have an increased risk for type 2 dia-
betes mellitus, cardiovascular disease and metabolic syn-
drome years after pregnancy, also offspring of GDM
women have a higher risk for noncommunicable diseases
and obesity rates [2].
Carotid intima-media thickness (cIMT) is measurement
of the combined thickness of the intimal and medial layers
of the carotid artery by B-mode ultrasound. cIMT is a
noninvasive technique to dectect subclinical atheroscler-
osis [3], and is associated with multiple cardiovascular risk* Correspondence: xiaoyb@vip.sina.com
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unless otherwise stated.factors [4], cardiovascular events [5] and coronary ar-
tery diseases [6].
As GDM alone is independent predictors of obstruct-
ive coronary artery disease [7] and cardiovascular dis-
eases. We suspect whether there is a direct correlation
between GDM and elevated cIMT. However, studies fo-
cusing on this issue have been small and have reported
conflicting results. Therefore, we conducted a meta-
analysis to assess the correlation between GDM and
cIMT.Methods
Literature search
We searched the databases of EMBASE and PubMed
and references lists of relevant papers to MAY 24,
2014. EMBASE search terms were ‘pregnancy diabetes
mellitus’/exp and ‘arterial wall thickness’/exp. Similar
search terms were used for PubMed. The search strategyhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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terial. No language and time limitation was performed.
Study selection
We selected published trials that investigated the rela-
tionship between gestational diabetes and cIMT. Ex-
cluded were (1) studies published as conference articles;
(2) cIMT was not measured in both gestational diabetes
and control groups; and (3) reports having duplicate
study population. All literature searches were independ-
ently reviewed by 2 authors (JW L and SY H) to identify
relevant trials that met the inclusion criteria. Disparities
were adjudicated by a third author (YB X). For each in-
cluded article, study characteristics, including authors,
publication year, country, ages, duration, BMI, mean and
standard deviation of CIMT were extracted independ-
ently by two researchers (JW L and SY H). If the studies
were studying the same population, we included the
newer and completed ones in this meta-analysis.
Statistical analysis
The cIMT in both gestational diabetes and control groups
were induced to our meta-analysis. Statistical hetero-
geneity between studies was tested by Cochran’s test
(P < 0.05). We used the random-effect model in this
meta-analysis, which takes into account heterogeneity
among studies, because the study design and measur-
ing time were different across studies. The Cochrane Q
test and I2 was used to evaluate the presence of hetero-
geneity. If heterogeneity exists, subgroup analyses wereFigure 1 Literature search and selection process.conducted to evaluate effect modification by study-
level characteristics including publish year, number of
patients, ages at pregnancy, measuring time (in pregnancy
or after pregnancy), BMI and duration. Publication bias
was assessed with Egger’s test. All statistical significance
was set at a p value of 0.05, and CIs were calculated at
the 95% level. Statistical analyses were performed with
Stata software (version 11.0; Stata Corporation, College
Station, TX).
Results
Search results and study characteristics
A total of 67 articles were identified in a combined search
of PubMed and EMBASE. We also manually searched
studies cited in previous reviews and of references list
from retrieved articles. First 27 duplicates were removed,
and then 18 articles were initially excluded through
screening title and abstract. Among the 23 articles re-
trieved for further review of the full text, 6 were excluded
for repeated reports, 1 for not reporting cIMT outcomes,
and 1 study for conference reports. Akinci B and his col-
leagues investigated the association between GDM and
CVD from different aspects and published five articles
using the same population [1,8-11]. Mehmet Vural and
his colleagues [12] studied the same population with
Mehmet Ali Eren [13]. Eventually, 15 studies with a total
of 2247 subjects were included in our meta-analysis
(Figure 1) [11,13-26]. Study characteristics and exclusion
criteria included in the analysis are shown in Table 1. Only
the study of Gunderson [19] was evalauted at multivariate
Table 1 Study characteristics of included studies
Author Age No. patient Country Duration(year) BMI Waist Exclusion:
GDM CG GDM CG
Baris Akinci [11] 35.1 190 Turkey 3.39 26.82 ± 4.25 26.5 ± 2.66 90.31 ± 11.68 87.45 ± 8.93 known cardiovascular disorders, type 1 or type 2
diabetes (diagnosed before the index pregnancy), familial
hyperlipidemia, hypertension, acute infection, chronic
inflammatory disease, coagulation disorders and other
systemic diseases, on peri- or postmenopausal period at
the time of sampling
A.E. Atay [14] 27.9 75 Turkey 2.29 32.2 ± 4.8 27.3 ± 4.2 receiving any medication during the last 3 months,
with liver or renal dysfunction, hyperprolactinemia, or
thyroid disease and smokers, with GDM and healthy
pregnant women with a history of GDM in their
previous pregnancies or glucose tolerance before the
present pregnancy, healthy pregnant women with a
family history of DM
S. Bo [15] 41.1 195 Italy 6.5 Group 1: 20.2 ± 2.2
Group 2: 23.6 ± 5.2
22.1 ± 3.1 Group 1: 73.6 ± 5.7
Group 2: 86.4 ± 13.5
79.9 ± 9.9 known pre-pregnancy conditions, such as diabetes mellitus,
diseases affecting glucose metabolism, hypertension,
chronic illness, and medical treatments (including
hormonal preparations), presence of a positive OGCT,
but an OGTT not diagnostic for GDM.
Mustafa Caliskan [16] 33.4 95 Turkey 6 26.9 ± 3.9 26.1 ± 2.7 85.0 ± 5.9 84.4 ± 4.9 presence of a valvular or congenital heart disease;
cardiac rhythm other than sinus; previous myocardial
infarction; hypo- or hyperthyroidism; chronic obstructive
pulmonary disease or corulmonale; systemic diseases (etc.
hemolologic ,hepatic, and renal diseases) or any disease
that could impair coronaryflow reserve; hypertrophic
cardiomyopathy; family history of coronary artery disease;
excessive alcohol consumption (>120 g/day); previous
lipid metabolism disorders; history of dyslipidemia;
smoking; and diabetes mellitus.those with ST seg-
ment or T-wave changes specific for myocardial ischemia,
Q-waves, and incidental left bundle branch block on ECG
Mehmet Ali Eren [13] 31 64 Turkey 0 31.8 ± 5.5 29.4 ± 5.4 smoking, alcohol abuse, preeclampsia, multiple
pregnancies, pregestational diabetes for all study
participants, and a family history of diabetes mellitus (for
the control group only), pregnancies with GDM who had
overt diabetes with 75-g standard OGTT in the 6-week
after delivery
Hossein Fakhrzadeh [17] 33 40 Iran 4 27.63 ± 3.52 27.33 ± 5.64 current or previous smokers, patients who had pre-




35.7 139 Brazil 2.7 29.01 ± 0.66 22.46 ± 0.42 92.09 ± 1.63 74.08 ± 1.14 any past condition afflicting them at previous
pregnancies, other than GDM, was considered an
exclusion criteria, especially those requiring hospital
admission such as preeclampsia. alcoholism, drug
addiction, uremia as well as those with liver, psychiatric,



















Table 1 Study characteristics of included studies (Continued)
Erica P. Gunderson [19] 44.2 898 USA 20 24.8 (5.6) 23.3 (4.3) 74.4 (11.1) 71.7 (8.8) heart disease or diabetes before pregnancies andthose
without any post-baseline births,missing ccIMT mea-
surements, and with history of heart disease,recently or
currently pregnant, and with previous hysterectomy at
baseline, with clinically relevant diabetes at baseline
and those who developed diabetes before the first
post-baseline birth
H Ijas [20] 52.2 116 Finland 19 27.1 ± 5.3 24.5 ± 4.2 94.4 ± 14.9 94.4 ± 14.2 GDM diagnosed in their subsequent pregnancy
Ufuk Ozuguz [22] 30.1 101 Turkey 0 29.95 ± 4.21 26.34 ± 4.08 previously knowndiagnosis of diabetes mellitus; the
presence of an additional cardiovascular risk factor such
as hypertension, hyperlipidemia or coronary artery
disease; presence of other factors that may affect serum
lipid profile and/or hsCRP level (acetylsalicylic acid,
smoking, impaired liver and kidney functions, history of
trauma, an acute infection within one month prior to
presentation or a chronic infection); presence of an
underlying chronic inflammatory condition such as
collagen tissue and inflammatory bowel diseases.
E. TARIM [23] 29.4 70 Turkey 0 28.65 ± 4.75 27.17 ± 2.90 smokers, patients who had folic acid and vitamin B12
deficiency, hypertension, multiple pregnancy, fetal
abnormalities, pre-existing hypertension and diabetes,
thyroid disease or a history of significant severe diseases,
family history of coronary heart disease and stroke
I Vastagh [24] 32.2 42 Hungary 0 28 ± 4 27 ± 4 have a history of diabetes mellitus or a previous GDM.
Gholamreza
Yousefzadeh [26]
24.8 50 Iran 0 28.7 ± 4.5 26.5 ± 4.5 family history of cardiovascular disorders; history of
hypertension; anti-hypertensive and cholesterol medication
use; hyperlipidemia; overt diabetes or fasting plasma
glucose (FPG) > 125 mg/dl;chronic renal or hepatic
diseases; malignancies; recent hormonal medications;
cigarette smoking; severe obesity (body mass index
[BMI] >35 kg/m2); and history of infertility or polycystic
ovarian disease, with the status of plaques/shadowing
( > 1.0 mm) at any carotid site
Volpe, L. [25] 36.3 52 Italy 2 25.7 ± 8.9 23 ± 3.4 86.9 ± 9.7 79.6 ± 9.7 not mentioned
Yun Hyi Ku [21] 32.3 120 Korea 1 22.3 (20.4-24.2) 20.4 (19.5-23.1) 80.3 ± 7.7 74.5 ± 7.7 females who were diagnosed with gestational diabetes
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BMI, HOMA-IR, weight gain, year 20-HOMA-IR +
DBP, incident diabetes and metabolic syndrome), other
studies used unadjusted data. Other characteristics of
included studies have been put into the supplemental
material (Additional file 2).
GDM is associated with cIMT
The cIMT from both GDM and control groups was pooled.
The WMD was 0.05 (95% CI: 0.03–0.07, P < 0.001). The
statistic value I2 was 92.5%, P < 0.001 (Figure 2). No sig-
nificant publication bias was found for WMD by Begg’s
test (P = 0.621) (Figure 3). We performed meta-regression
analyses on cIMT to investigate the cause of heterogen-
eity, and found the BMI may be one of the main causes
(P = 0.048, Table 2). Subgroup analysis was performed to
distinguish the heterogeneity among these studies. Re-
sults showed that study object with higher BMI got lar-
ger cIMT (WMD: 0.07, 95% CI: 0.03–0.12 for those
with BMI > 27.6 and WMD: 0.04, 95% CI: 0.02–0.06 for
those with BMI < 27.6). Diagnostic criteria of GDMFigure 2 Forest plots showing effects of GDM on cIMT.might influence the results (WMD: 0.08, 95% CI: 0.05–
0.11 for Carpenter and Coustan criteria, WMD: 0.03,
95% CI: −0.01–0.07 for NDDG criteria, WMD: 0.04, 95%
CI: −0.01–0.09 for WHO criteria and WMD: 0.01, 95%
CI: −0.06–0.07 for ADA 75 g criteria). There seemed no
difference as to measuring time of cIMT with GDM
(WMD: 0.07, 95% CI: 0.03–0.10 when measured in preg-
nancy and WMD: 0.05, 95% CI: 0.03–0.07 when measured
years after pregnancy) and ages at pregnancy (WMD: 0.07,
95% CI: 0.03–0.11 for those with age < 31 and WMD:
0.04, 95% CI: 0.02–0.07 for those with age > =31). The
GDM did not significantly increase cIMT as to publish
year (WMD: 0.07, 95% CI: 0.03–0.10 for those published
after 2013 and WMD: 0.05, 95% CI: 0.02–0.08 for those
before 2013), number of patients (WMD: 0.06, 95% CI:
0.03–0.08 for number of patients above 90 and WMD:
0.05, 95% CI: 0.02–0.07 for number of patients below 90)
and duration between the time of GDM diagnosed and
cIMT measured (WMD: 0.05, 95% CI: 0.01–0.09 for dur-
ation > 4 and WMD: 0.05, 95% CI: 0.01–0.09 for duration
between 0 and 4) (Table 3).
Figure 3 Begg’s funnel plot showing publication bias.
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During pregnancy, insulin resistance increases. In healthy
women compensatory insulin secretion counteracts this
demand, while in GDM patients, not enough insulin is
secreted to overcome the insulin demand. Compared
with healthy ones, GDM patients are more likely to have
type 2 diabetes and endothelial dysfunction, known con-
ditions that leads to higher risk for cardiovascular dis-
eases [27].
The results from our systematic review and meta-
analyses indicate GDM was significantly associated with
elevated cIMT, and this association already exists at the
time of pregnancy. Fatty women with GDM seem to
have larger cIMT.
Most of our included studies have found GDM is asso-
ciated with larger cIMT. The study by A.E. Atay et al.
[14] was the one finding the most significant difference
of cIMT between GDM patients and control. The study
population included in this study was fatter (BMI: 32.2 ±
4.8 for the GDM group vs 27.3 ± 4.2 for the control).
Earlier study has found that obese patients with GDMTable 2 Results of meta regression of GDM on cIMT
Item Coef P 95% CI
Publish year .0005284 0.930 -.0121875 .0132443
Age at pregnancy -.0017171 0.704 -.0112528 .0078185
No. Patients -.0000597 0.372 -.0001991 .0000797
BMI of GDM .0100715 0.048 .0001263 .0200168
Measuring time .013057 0.676 -.0529943 .0791082
Duration -.0005414 0.823 -.0056708 .0045881
GDM Criteria -.0234964 0.062 -.0484176 .0014249
Coef = regression coefficients.
CIs = confidence intervals.had higher prevalence of chronic hypertension [28] and
cardiovascular disease [29]. Our meta-regression and
subgroup analyses confirms that the association be-
tween GDM and cIMT is influenced by BMI. The study
of H Ijas et al. [20] showed that GDM patients with
BMI > 25 had larger cIMT compared with those with
BMI < 25 and controls. Also Gunderson and his col-
leagues [19] has found the association between GDM
and cIMT changed from significance to insignificance
after adjusting BMI. The study by Yun Hyi Ku [21]
found there was no association between GDM and
cIMT. As this study was conducted in Korea, the au-
thor compared their results with western ones and in-
ferred it may be caused by culturally-based obesity. The
author explained that as obesity was one of the major
factor influencing cIMT, obesity is much less common
in their country than in western ones ( BMI of study
objects were in normal range), which may lead to insig-
nificance of their results. Contrary to these findings,
the study of S. Bo et al. [15] found that GDM patients
with BMI ≥ 25 had smaller cIMT that those with BMI <
25. This study regarded both BMI and metabolic syn-
drome as grouping criteria and BMI < 25 group also
had no components of the metabolic syndrome. Metabolic
syndrome may abolish this connection in this study.
We find that the diagnostic criteria of GDM may in-
fluence the impact of GDM on cIMT. Diagnosis of ges-
tational diabetes significantly changed on the basis of
the diagnostic criteria used, and influenced clinical out-
comes [30,31]. However, too few studies included in
NDDG, WHO, ADA 75 g subgroups. In fact the NDDG
criteria indicate more severe GDM than Carpenter-
Coustan one. But we got no statistically different result
in NDDG subgroup analysis, while a statistically different
one in Carpenter-Coustan subgroup. The heterogeneity
Table 3 Stratified analyses of GDM on cIMT
Item Subgroup No WMD 95% CI P. Het I2 P. test
Publish year > = 2013 5 0.07 0.03 0.10 <0.001 92.2 0.001
<2013 10 0.05 0.02 0.08 <0.001 88.8 <0.001
No. pat > = 90 8 0.05 0.02 0.07 <0.001 94.3 <0.001
<90 7 0.07 0.03 0.10 <0.001 79.9 <0.001
Ages at pregnancy > = 31 8 0.04 0.02 0.07 <0.001 85.4 0.001
<31 7 0.07 0.03 0.11 <0.001 94.9 <0.001
Measuring time In pregnancy 5 0.07 0.03 0.10 <0.001 91.7 <0.001
After pregnancy 10 0.05 0.03 0.07 <0.001 85.2 0.001
Duration (years) >4 4 0.05 0.01 0.09 <0.001 92.1 0.007
>0, <4 6 0.05 0.01 0.09 <0.001 91.6 0.010
BMI > = 27.6 7 0.07 0.03 0.12 <0.001 95.1 0.001
<27.6 8 0.04 0.02 0.06 <0.001 83.8 0.001
GDM Criteria Carpenter 7 0.08 0.05 0.11 <0.001 90.5 <0.001
NDDG 3 0.03 <−0.01 0.07 0.001 85.2 0.072
WHO 2 0.04 −0.01 0.09 0.102 62.6 0.114
ADA-75 g 4 0.01 −0.06 0.07 <0.001 93.5 0.816
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cause this phenomenon.
The American Heart Association recommend to pre-
vent heart disease in women with gestational diabetes,
which was based on a higher risk of type 2 diabetes mel-
litus in these persons [32]. It is reported that cIMT adds
predictive value to the Framingham risk score for car-
diovascular events [5], is a level IIa recommendation for
cardiovascular risk evaluation [33], cIMT has been con-
firmed to be able to predict incident coronary heart dis-
eases [34]. Our finding that GDM is associated with
early atherosclerosis even during pregnancy is important,
because we can establish prevention strategy, such as
weight control for GDM patients earlier in life.
Our research also finds increase of cIMT already exists
at the time pregnancy. Another question raises our in-
terests is that whether cIMT can predict GDM, as it’s
demonstrated that cIMT is elevated before the onset of
clinical diabetes [35]. However, cIMT measured prior to
the pregnancy fails to predict pregnancy outcome such
as gestational diabetes [36]. Thus subclinical atheroscler-
osis may appear along with GDM, but is not a predictor
of GDM. We find cIMT does not increase years after
GDM has been diagnosed. A possible explanation is that
these patients take certain drugs to delay the process of
atherosclerotic formation, it’s been reported that even
subclinical atherosclerosis may be reduced by drugs [37].
As the medications of these patients were not fully re-
ported in included studies, future researches are needed
to study this issue.
The number of population in each study is limited;
there was no study with number of GDM patientsbeyond 200. Prospective study of large samples is
needed in the future.
Conclusion
In this meta-analysis we observed GDM is related to
larger cIMT, the relation is stronger in obese GDM pa-
tients, and the association already exists at the time of
pregnancy and remained significant years after preg-
nancy. Weight control may be helpful to prevent cardio-
vascular diseases for GDM patients.
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